Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature

Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report cases from our institute with colorectal cancer who experienced severe toxicities to standard dose 5-FU based chemotherapy. <i>DPYD</i> gene sequen...

Full description

Bibliographic Details
Main Authors: Nedal Bukhari, Abdulraheem Alshangiti, Emad Tashkandi, Mohammed Algarni, Humaid O. Al-Shamsi, Hamoud Al-Khallaf
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Clinics and Practice
Subjects:
dihydropyrimidine dehydrogenase
5-Fluorouuracil
chemotherapy
DPYD
polymorphism
Online Access:https://www.mdpi.com/2039-7283/11/3/62
Description
Summary:Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report cases from our institute with colorectal cancer who experienced severe toxicities to standard dose 5-FU based chemotherapy. <i>DPYD</i> gene sequencing revealed rare different polymorphisms that prompted dose adjustments of administered 5-FU and capecitabine. To our knowledge, this is the first case series looking at <i>DPYD</i> polymorphisms in the Saudi Arabian population.
ISSN:2039-7283

Similar Items